Galapagos

Generaal De Wittelaan L 11A3

2800 Mechelen

BE

Galapagos

Foundation date

30/06/1999

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Galapagos seeks to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biotechnological company, focused on the development and commercialization of novel medicines that will improve people’s lives.

Latest news

  • New software from UHasselt and ZEISS shows in sharp detail how biomolecules move in cells.

    21 hours ago

  • Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

    22 hours ago

  • VIB-KU Leuven study reveals FUS protein’s role in ALS and FTD

    Friday June 14th 2024